In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. David Cibula to discuss the international ABRAX study. Dr. Cibula is the Chair of the Gynecologic Oncology Center at the General Faculty Hospital in Prague, Chair of the Central and Eastern European Gynaecologic Oncology Group (CEEGOG), as well as a Former ESGO president.

Highlights:
* ABRAX trial was designed to evaluate if the completion of radical hysterectomy is associated with a survival benefit in patients with early-stage cervical cancer and positive pelvic lymph node found intraoperatively.
* This trial represents the largest cohort of patients managed by upfront surgery with negative lymph nodes on preoperative staging but positive lymph node involvement diagnosed during surgery.
* We did not find any improvement in PFS, OS, or pelvic disease-free survival associated with radical hysterectomy, either in the whole group or in any subgroups, including patients with larger tumor size or adenocarcinomas.
* The outcome of the ABRAX trial is in agreement with current international guidelines (NCCN, ESGO-ESTRO-ESP) which recommend the abandonment of further radical surgery in patients with intraoperative N1 detection.